Cytodyn Inc (OP:CYDY)

Performance

52-Week Range 49.6% below 52-week high

0.2000

0.1852W Low 0.4052W High

1 Week 11.1% below 1-week high

0.191W Low 0.231W High

Cytodyn Inc (CYDY) traded between $0.18 and $0.40 over the past 52 weeks and last traded at $0.20, 49.6% below its 52-week high. Over the past week it ranged between $0.19 and $0.23.

Past 12 Months

-7.6%

-4.3%

-15.0%

-25.3%

-26.0%

-24.0%

1W -$0.02

1M -$0.01

3M -$0.04

6M -$0.07

YTD -$0.07

1Y -$0.06

CYDY was -24.0% over the past year, -25.3% over six months, -26.0% year to date, -7.6% in the last week.

12 Months vs Market

CYDY

-24.0%

DIA

+9.9%

SPY

+15.0%

QQQ

+23.7%

IWM

+15.4%

Over the past 12 months CYDY returned -24.0% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 0.96× 3-mo avg

Today 1,527,711 3-mo avg 1.6M

2.3M

1.7M

1.6M

1.9M

YTD

1.8M

CYDY most recently traded 1,527,711 shares against a 3-month average daily volume of 1.6M.

More News

CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th

September 15, 2026

From Virtual Investor Conferences

Life Sciences Virtual Investor Forum Agenda Announced

September 14, 2026

From Virtual Investor Conferences

CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab

September 01, 2026

CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease

June 11, 2026

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

June 04, 2026

From Natera, Inc.

Via Business Wire

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

June 03, 2026

NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation

June 03, 2026

CytoDyn to Present at the LD Micro Invitational XVI

May 15, 2026

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

June 03, 2026

From BioMedWire

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

May 11, 2026

InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates

May 11, 2026

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

May 11, 2026

From BioMedWire

CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer

April 27, 2026

CytoDyn to Host Investor Webcast

April 23, 2026

CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026

April 22, 2026

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

April 21, 2026

CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026

April 20, 2026

CytoDyn to Present at the AACR Annual Meeting 2026

April 14, 2026

CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer

March 24, 2026

CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab

March 05, 2026

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

February 20, 2026

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

January 27, 2026

December 2025 Letter to Shareholders

December 16, 2025